Is there a role for B lymphocyte chimerism in the monitoring of B-acute lymphoblastic leukemia patients receiving allogeneic stem cell transplantation?. Issue 1 (March 2015)

• Record Type: Journal Article
• Authors: Yang, Yi-Ning; Wang, Xiao-Rui; Qin, You-Wen; Wan, Li-Ping; Jiang, Ying; Wang, Chun
• Is Part Of: Chronic diseases and translational medicine. Volume 1:Issue 1(2015)
• Page Start: 48
• Page End: 54
• Publication Date: 2015-03
• Subjects: B cell acute lymphoblastic leukemia (B-ALL) -- B-cell -- T-cell -- Chimerism -- Allogeneic hematopoietic stem cell transplantation (allo-HSCT); Chronic diseases -- Periodicals; Medicine -- Research -- Periodicals; Chronic diseases; Medicine -- Research; Chronic Disease; Translational Medical Research; Periodicals; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.044
• DOI: 10.1016/j.cdtm.2015.02.004
• Languages: English
• ISSNs: 2095-882X

Abstract

Abstract: Objective: To determine the sensitivity and significance of B-cell chimerism for the detection of early engraftment, transplant rejection, and disease relapse. Methods: The dynamic monitoring of lineage-specific cell subtypes (B, T, and NK cells) was made in 20 B-cell acute lymphoblastic leukemia (B-ALL) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the early period after allo-HSCT, the latest establishment of B-cell complete chimerism (CC) was observed in a majority of patients. Results: The percentage of donor cells of B-cell lineage was lower than the percent of T-cell lineage in most of the mixed chimerism (MC) patients. During graft rejection, the frequency of patients with decreasing MC of B-, T- and NK-cell lineage were 5/5, 2/5, and 2/5. When disease relapsed, five patients showed a faster decrease of the donor percent of B-cells than of T- or NK-cells. Only one patient displayed a more rapid decrease in NK-cells than in T- or B-cells. Conclusion: Monitoring of B-cell chimerism after HSCT seems to be valuable for insuring complete engraftment, anticipating graft rejection, and relapse in B-ALL patients.